Search results for boehringer ingelheim
Boehringer Ingelheim's investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivota
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Boehringer Ingelheim announced that the European Commission has granted marketing authorisation of the novel, oral direct thrombin inhibitor, Pradaxa® (dabigatran etexilate) in all 27 EU member state
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Apt
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual d
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The Scottish Medicines Consortium (SMC) has accepted Pradaxa® (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the pr
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The 2008 Boehringer Ingelheim FENS Research Award goes to Pascal Fries, MD, PhD, from the F.C. Donders Centre for Cognitive Neuroimaging in Nijmegen, The Netherlands. At the Congress of the Federatio
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
After careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 (+9.0%). On account of the strength of the euro against the US dollar and
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular p
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
Boehringer Ingelheim has signed a licence agreement with Evec, Inc., Japan, for one of its fully-human therapeutic antibody programmes. Based on the agreement, Boehringer Ingelheim will obtain worldw
read more » Discuss Add this link to... Bury
